Akari Therapeutics PLC ADR | Ownership
Companies that own Akari Therapeutics PLC ADR
Shigeta Yasumitsu (Investment Portfolio)
843,849
5.53%
207,506
0.15%
06/30/2018
Endurant Capital Management LP
180,297
1.18%
-17,200
0.13%
06/30/2018
Baker Bros. Advisors LP
58,770
0.39%
-281,063
0%
06/30/2018
Millennium Management LLC
35,343
0.23%
-135,279
0%
06/30/2018
BMO Asset Management, Inc.
30,000
0.2%
0
0%
06/30/2018
Virtu Financial BD LLC
29,800
0.2%
29,800
0%
06/30/2018
Parallax Volatility Advisers LP
7,500
0.05%
0
0%
06/30/2018
UBS Securities LLC
2,810
0.02%
2,810
0%
06/30/2018
Morgan Stanley Smith Barney LLC (Private Banking)
229
0%
0
0%
06/30/2018
Woodbury Financial Services, Inc.
25
0%
0
0%
06/30/2018
| Address |
75/76 Wimpole Street
London London & South East W1G 9RT
United Kingdom
|
|
Employees
|
- |
| Website |
http://akaritx.com |
| Updated |
07/08/2019 |
| Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Coversin, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom. |
